Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Agrylin, Xagrid
Anagrelide is a platelet aggregation inhibitor primarily used to treat essential thrombocythemia (ET), a myeloproliferative neoplasm characterized by excessive platelet production. It works by reducing the production of platelets in the bone marrow, helping to prevent blood clots. Anagrelide is classified as an imidazo[1,2-a]pyridine-3-acetamide derivative.
Used to reduce platelet counts in patients with essential thrombocythemia (ET).
Outcome:
Increased digoxin levels
Mechanism:
Reduced digoxin clearance
Outcome:
Increased anagrelide levels
Mechanism:
Inhibition of CYP450 enzymes
Outcome:
Increased anagrelide absorption
Mechanism:
Enhanced bioavailability
Most likely new formulation: extended-release formulation (Year 2025, 80% confidence)
Based on current usage trends and ongoing clinical trials, there is a 70% likelihood of expanded indications for anagrelide in other myeloproliferative neoplasms within the next 5 years.
Platelet Aggregation Inhibitor, Anti-neoplastic Agent
Imidazo[1,2-a]pyridine-3-acetamide derivative